Ofatumumab versus Teriflunomide in Multiple Sclerosis


Hauser S. L. , Bar-Or A., Cohen J. A. , Comi G., Correale J., Coyle P. K. , ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.383, no.6, pp.546-557, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 383 Issue: 6
  • Publication Date: 2020
  • Doi Number: 10.1056/nejmoa1917246
  • Title of Journal : NEW ENGLAND JOURNAL OF MEDICINE
  • Page Numbers: pp.546-557

Abstract

BackgroundOfatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known.